# Sema4

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sema4

- Industry: Healthcare IT
- Headquarters: Stamford, US
- Website: www.sema4.com
- Total disclosed funding: $241M
- Latest round: Series C (Jul 28, 2020)
- Investors on record: 8

## About

Based in Connecticut, US, and founded in 2017, Mount Sinai Genomics, Inc., doing business as Sema4, operates as a developer of genomics diagnostic testing solutions for medical areas such as biopharma, oncology, women's health, covid 19 and hereditary cancer.

## Funding rounds

- Series C, Jul 28, 2020, $121M — Blackstone Group, Connecticut Innovations, BlackRock, Decheng Capital, Deerfield Management, Oak HC/FT, Section 32, Moore Strategic Ventures
- Series B, Aug 18, 2019, $120M — Blackstone Group, Connecticut Innovations, Decheng Capital, Oak HC/FT, Section 32

## Investors

- Blackstone Group (https://capitalatlas.ai/funds/blackstone-group) — Series B, Series C
- Connecticut Innovations (https://capitalatlas.ai/funds/connecticut-innovations) — Series B, Series C
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series B, Series C
- Oak HC/FT (https://capitalatlas.ai/funds/oak-hc-ft) — Series B, Series C
- Section 32 (https://capitalatlas.ai/funds/section-32) — Series B, Series C
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series C
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series C
- Moore Strategic Ventures (https://capitalatlas.ai/funds/moore-strategic-ventures) — Series C